Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Cathy Kelly

Senior Writer

Washington, DC
Cathy Kelly has been covering reimbursement and market access news for more than a decade for "The Pink Sheet" and other publications that are now part of Informa's pharmaceutical intelligence resources. Her expertise spans legislative, regulatory and public policy topics as well as coverage trends in public and private insurance markets. Cathy is especially interested in following the ongoing transformation of the US health care system and its effect upon major stakeholders in the biopharma industry. She is based in Washington D.C.
Advertisement
Set Alert for Articles By Cathy Kelly

Latest From Cathy Kelly

ICER Revising Drug Review Criteria, Will Use Net Prices, Broad Evidence Base

Proposed updates to group’s cost effectiveness evaluations will guide reviews during 2017-2019. Ultra-orphan drug will be assessed with different standards.

Cost Effectiveness Pricing Strategies

Ovarian Cancer Drugs Will Get ICER Review As Olaparib's Maintenance Indication Looms

PARP inhibitors from Tesaro, Clovis, and AstraZeneca have been tentatively chosen for the evaluation.

Pricing Strategies Reimbursement

Medicaid Drug Rebates Will Get Closer Scrutiny From CMS, Verma Pledges

CMS Administrator-nominee Seema Verma promises stronger agency oversight of Medicaid drug rebate program in response to question from Sen. Grassley during Senate confirmation hearing.

Policy Medicaid

US Medicaid Reform: Legislators Caution CMS Nominee About Coverage Loss

Seema Verma is closely identified with Medicaid reform but both Republicans and Democrats expressed concern during her Senate confirmation hearing that reforms not translate into loss of insurance coverage.

Policy Medicaid

Part Of The Solution? PBMs See Opportunities In Medicaid Reform

Amidst a growing chorus of criticism that pharmacy benefit managers are contributing to the problem of high drug costs, PCMA’s Merritt defends the PBM business model and points to its potential for better managing costs in Medicaid.

Pharmacy Benefit Management Pricing Debate

MS Patient Treatment Preferences Diverge From Payers, Physicians

Survey finds patient assign greatest value to a drug’s effect on multiple sclerosis symptoms.

Health Technology Assessment Comparative Effectiveness
See All
Advertisement
UsernamePublicRestriction

Register